Crinetics Pharmaceuticals has received FDA approval for Palsonify (paltusotine), marking its first approved product and the premier oral first-line therapy for adults with acromegaly who are ineligible for surgery or did not respond adequately. This once-daily pill addresses a rare endocrine disorder caused by excessive growth hormone from the pituitary gland. Crinetics’ entry introduces direct competition against established injectable blockbuster drugs from Novartis and Ipsen. The approval followed positive results from late-stage trials demonstrating significant growth hormone reduction and a favorable safety profile, heralding a new oral therapeutic option for this rare disease population.